Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

LUMO - LUMOS PHARMA, INC.

IEX Last Trade
3.85
0   0%

Share volume: 0
Last Updated: Wed 11 Dec 2024 09:35:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$3.85
0.50
0.11%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 6%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0.93%
3 Months
15.43%
6 Months
91.19%
1 Year
42.76%
2 Year
20.89%
Key data
Stock price
$3.85
P/E Ratio 
0.00
DAY RANGE
$3.85 - $4.34
EPS 
$0.00
52 WEEK RANGE
$1.53 - $4.58
52 WEEK CHANGE
$42.76
MARKET CAP 
31.684 M
YIELD 
N/A
SHARES OUTSTANDING 
8.124 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.32
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$159,018
Company detail
CEO: Richard J. Hawkins
Region: US
Website: lumos-pharma.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren.

Recent news